Literature DB >> 9420717

Myocardial technetium 99m-labeled teboroxime clearance derived from canine scans differentiates severity of stenosis after dipyridamole.

G Johnson1, D K Glover, C B Hebert, R D Okada.   

Abstract

BACKGROUND: The purposes of this study were to determine (1) whether perfusion defects and differential teboroxime clearance observed on serial postdipyridamole planar gamma camera images have utility in differentiating severity of coronary stenosis in canine myocardium and (2) whether single-zone (99mTc activity in one zone over time) or dual-zone (99mTc activity ratio in two zones over time) quantitative analysis provides the most useful characterization of teboroxime clearance kinetics. METHODS AND
RESULTS: Accordingly, eight dogs received a mild coronary stenosis (microsphere-determined, post-dipyridamole flow > or = 0.4 ml/min/gm) and 10 dogs received a severe coronary stenosis (flow < or = 0.3 ml/min/gm). In three control dogs there was no coronary stenosis. Teboroxime (5 mCi) was injected after dipyridamole (0.8 mg/kg/min), and gamma camera imaging was begun immediately and continued for 60 minutes. Quantitative analysis of single-zone clearance curves indicated that teboroxime retention for both zones of stenosis (mild = 66.3% +/- 2.8%, SEM; severe = 69.5% +/- 3.7%) was significantly greater than control zone retention (54.5% +/- 3.0%; p < 0.05) at 10 minutes. Retention in mild (37.2% +/- 1.9%, SEM) and severe (42.3% +/- 1.5%) zones of stenosis was significantly different from each other at 60 minutes (p < 0.05). There was a significant direct, linear correlation of flow with teboroxime clearance at 20 minutes (r = +0.74, normal and ischemic zones). Quantitative analysis with dual-zone count ratios (stenosed/normal) demonstrated significant differences among control (0.93 +/- 0.04, SEM), mild stenoses (0.54 +/- 0.04), and severe stenoses (0.39 +/- 0.03) as early as 2 minutes after administration of 99mTc-labeled teboroxime. The correlation coefficient for flow ratio versus dual-zone counts/pixel ratio at 20 minutes was r = +0.74.
CONCLUSION: Thus in this canine stenosis model with dipyridamole, gamma camera imaging could distinguish mild from severe coronary stenoses by either single- or dual-zone analysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9420717     DOI: 10.1007/bf02939955

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  22 in total

1.  Myocardial clearance kinetics of technetium-99m-SQ30217: a marker of regional myocardial blood flow.

Authors:  R E Stewart; M Schwaiger; G D Hutchins; P C Chiao; K P Gallagher; N Nguyen; N A Petry; W L Rogers
Journal:  J Nucl Med       Date:  1990-07       Impact factor: 10.057

2.  Diagnostic value of a new myocardial perfusion agent, teboroxime (SO 30,217), utilizing a rapid planar imaging protocol: preliminary results.

Authors:  R C Hendel; B McSherry; M Karimeddini; J A Leppo
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

3.  Comparison of technetium-99m teboroxime tomography with automated quantitative coronary arteriography and thallium-201 tomographic imaging.

Authors:  R M Fleming; R L Kirkeeide; H Taegtmeyer; A Adyanthaya; D B Cassidy; R A Goldstein
Journal:  J Am Coll Cardiol       Date:  1991-05       Impact factor: 24.094

4.  Technetium-99m teboroxime scintigraphy. Clinical experience in patients referred for myocardial perfusion evaluation.

Authors:  L Bontemps; X Geronicola-Trapali; Y Sayegh; O Delmas; R Itti; X André-Fouët
Journal:  Eur J Nucl Med       Date:  1991

5.  Myocardial extraction of teboroxime: effects of teboroxime interaction with blood.

Authors:  W L Rumsey; K C Rosenspire; A D Nunn
Journal:  J Nucl Med       Date:  1992-01       Impact factor: 10.057

6.  Comparison between thallium-201, technetium-99m-sestamibi and technetium-99m-teboroxime planar myocardial perfusion imaging in detection of coronary artery disease.

Authors:  R Taillefer; R Lambert; R Essiambre; D C Phaneuf; J Léveillé
Journal:  J Nucl Med       Date:  1992-06       Impact factor: 10.057

7.  Early myocardial clearance kinetics of technetium-99m-teboroxime differentiate normal and flow-restricted canine myocardium at rest.

Authors:  G Johnson; D K Glover; C B Hebert; R D Okada
Journal:  J Nucl Med       Date:  1993-04       Impact factor: 10.057

8.  Rapid redistribution of teboroxime.

Authors:  H Weinstein; S T Dahlberg; B A McSherry; R C Hendel; J A Leppo
Journal:  Am J Cardiol       Date:  1993-04-01       Impact factor: 2.778

9.  Tomographic myocardial perfusion imaging with technetium-99m teboroxime during adenosine-induced coronary hyperemia: correlation with thallium-201 imaging.

Authors:  A S Iskandrian; J Heo; T Nguyen; S Beer; V Cave; D Cassel; B B Iskandrian
Journal:  J Am Coll Cardiol       Date:  1992-02       Impact factor: 24.094

10.  Tomographic myocardial perfusion imaging with technetium-99m-teboroxime at rest and after dipyridamole.

Authors:  Q S Li; G Solot; T L Frank; H N Wagner; L C Becker
Journal:  J Nucl Med       Date:  1991-10       Impact factor: 10.057

View more
  4 in total

1.  Technetium 99m-N-NOET: although not equivalent to thallium-201, it still offers new opportunities.

Authors:  A J Sinusas
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

2.  Technetium 99m-labeled teboroxime: death in utero, infanticide, or failure to thrive?

Authors:  R J Burns
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

3.  Planar imaging of 99mTc-labeled (bis(N-ethoxy, N-ethyl dithiocarbamato) nitrido technetium[V]) can detect resting ischemia.

Authors:  G Johnson; K N Nguyen; Z Liu; P Gao; R Pasqualini; R D Okada
Journal:  J Nucl Cardiol       Date:  1997 May-Jun       Impact factor: 5.952

4.  Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium.

Authors:  David R Okada; Gerald Johnson; Robert D Okada
Journal:  EJNMMI Res       Date:  2014-08-01       Impact factor: 3.138

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.